ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup
This article was originally published in PharmAsia News
ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.
You may also be interested in...
FDA’s Arthritis Advisory Committee said May 9 that Pfizer had worded the second-line indication too broadly, and indicated that a 5 mg dose is to be preferred, at least to begin with, due to safety concerns.
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Singapore's ASLAN Pharmaceuticals Pte Ltd. has inked a licensing deal with Colorado-based Array BioPharma Inc. to develop Array's oral HER2/EGFR inhibitor ARRY-543, currently entering Phase II for solid tumors